# BridgeBio Pharma, Inc.: Form 8-K, filed Dec 6, 2022

- Company: [BridgeBio Pharma, Inc.](/companies/bbio.md) (CIK 1743881)
- Form: 8-K
- Filed: 2022-12-06
- Accepted by EDGAR: Dec 6, 2022, 17:04 ET
- Period: 2022-11-30
- Accession: 0001193125-22-299475
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1743881/000119312522299475/d423428d8k.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1743881/000119312522299475/

## Items reported

- Item 1.01: Entry into a material agreement
- Item 2.03: New direct financial obligation
- Item 9.01: Financial statements and exhibits

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1743881/000119312522299475/d423428d8k.htm

Filed Dec 6, 2022.
Source: SEC EDGAR, the filing index for accession 0001193125-22-299475. Last ingested by Listed: Nov 12, 2026, 17:56 ET. No prices; not investment advice.